12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

LDMP regulatory update

FDA accepted for review an NDA from Hisamitsu's Noven Pharmaceuticals Inc. for low-dose paroxetine mesylate to...

Read the full 66 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >